Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

Fig. 1

A Patients attack free 0–6 months after treatment initiation* and B with ≥ 70% attack rate reduction during treatment.* Data for all lanadelumab doses in the HELP study are pooled. OLE open-label extension, q2w every 2 weeks, q4w every 4 weeks. *Regular dosing stage for rollover patients in the HELP OLE study. †Only 1 Black/African American patient was in the lanadelumab 300 mg q2w treatment group. ‡Both Asian patients were in the lanadelumab 150 mg q4w treatment group

Back to article page